Amid federal pressure, more hospitals stop gender-affirming care for minors
-
By
-
Theresa Gaffney
-
February 5, 2026
-
Clinical Scorecard: In response to federal regulations, an increasing number of hospitals discontinue gender-affirming treatments for minors
At a Glance
| Category | Detail |
|---|
| Condition | |
| Key Mechanisms | |
| Target Population | Transgender minors seeking gender-affirming hormones and puberty blockers, particularly in states with restrictive laws. |
| Care Setting | |
Key Highlights
- Over 40 hospitals have paused or ceased gender-affirming care for minors since January 2023.
- Federal pressure has led to investigations of hospitals continuing to provide care, impacting patient access.
Guideline-Based Recommendations
Diagnosis
Management
- Gender-affirming hormones and puberty blockers should be provided based on established medical guidelines, including those from the Endocrine Society.
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Transgender adolescents and young adults seeking gender-affirming treatments.
Access to gender-affirming hormones and puberty blockers is increasingly restricted due to regulatory pressures.
Clinical Best Practices
- Ensure informed consent and comprehensive evaluation before initiating treatment.
- Maintain a supportive environment for transgender minors and their families, including mental health resources.
References
